A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis

ClinicalTrials.gov ID: NCT01320332

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01320332. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of ASP3291 Following a Single Oral Dose in Subjects With Ulcerative Colitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the pharmacokinetics (PK) and to assess safety and tolerability of a single dose of ASP3291 in subjects with ulcerative colitis.

Study identification

NCT ID: NCT01320332
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Telsar Pharma Inc.; Industry
Enrollment: 16 participants

Conditions and interventions

Conditions

Ulcerative Colitis

Interventions

ASP3291 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2010 (Type not available)
Primary completion: Aug 2011 (Actual)
Completion: Aug 2011 (Actual)
Last update posted: Jul 24, 2012

2010 – 2011

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Advanced Clinical Research Institute	Anaheim	California	92801	—
SNBL Clinical Pharmacology Center	Baltimore	Maryland	21201	—
Clinical Trials of Texas, Inc.	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01320332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 24, 2012 · Synced Nov 15, 2026